Pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-38431055, a novel GPR119 receptor agonist and potential antidiabetes agent, in healthy male subjects

Clinical Pharmacology and Therapeutics

Volumn 90, Issue 5, 2011, Pages 685-692

  Katz, L B ^a   Gambale, J J ^a   Rothenberg, P L ^a   Vanapalli, S R ^a   Vaccaro, N ^a   Xi, L ^a   Polidori, D C ^a   Vets, E ^b   Sarich, T C ^a   Stein, P P ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b SGS Life Science Services   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; JNJ 38431055; PEPTIDE YY; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXPOSURE; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; HUMAN EXPERIMENT; INSULIN RELEASE; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SUSPENSION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; BLOOD GLUCOSE; DOUBLE-BLIND METHOD; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HALF-LIFE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PEPTIDE YY; RECEPTORS, G-PROTEIN-COUPLED;

EID: 80054988309     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.169     Document Type: Article

References (42)

1. Leahy, J.L., Bonner-Weir, S. & Weir, G.C. Beta-cell dysfunction induced by chronic hyperglycemia. Current ideas on mechanism of impaired glucoseinduced insulin secretion. Diabetes Care 15, 442-455 (1992).
2. Rossetti, L., Giaccari, A. & DeFronzo, R.A. Glucose toxicity. Diabetes Care 13, 610-630 (1990). (Pubitemid 20169143)
3. Klein, R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 18, 258-268 (1995).
4. Gaede, P., Vedel, P., Larsen, N., Jensen, G.V., Parving, H.H. & Pedersen, O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 348, 383-393 (2003). (Pubitemid 36159355)
5. The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 44, 968-983 (1995).
6. The Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes therapy on the development and progression of diabetic nephropathy in the diabetes control and complications trial. Kidney Int. 47, 1703-1720 (1995).
7. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy in the diabetes control and complications trial. Ann Intern Med. 122, 561-568 (1995).
8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352, 837-853 (1998).
9. Stratton, I.M. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321, 405-412 (2000). (Pubitemid 30609442)
10. Engelstoft, M.S., Egerod, K.L., Holst, B. & Schwartz, T.W. A gut feeling for obesity: 7TM sensors on enteroendocrine cells. Cell Metab. 8, 447-449 (2008).
11. Godlewski, G., Offertáler, L., Wagner, J.A. & Kunos, G. Receptors for acylethanolamides-GPR55 and GPR119. Prostaglandins Other Lipid Mediat. 89, 105-111 (2009).
12. Ahrén, B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat. Rev. Drug Discov. 8, 369-385 (2009).
13. Overton, H.A., Fyfe, M.C. & Reynet, C. GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity. Br. J. Pharmacol. 153 (suppl. 1), S76-S81 (2008). (Pubitemid 351340991)
14. Jones, R.M. & Leonard, J.N. The emergence of GPR119 agonists as anti-diabetic agents. Ann Reports in Medicinal Chem. 44, 149-170 (2009).
15. C hu, Z.L. et al. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology. 148, 2601-2609 (2007).
16. Chu, Z.L. et al. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release. Endocrinology 149, 2038-2047 (2008).
17. Lauffer, L.M., Iakoubov, R. & Brubaker, P.L. GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes. 58, 1058-1066 (2009).
18. Drucker, D.J. & Nauck, M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368, 1696-1705 (2006). (Pubitemid 46048557)
19. Holst, J.J. The physiology of glucagon-like peptide 1. Physiol. Rev. 87, 1409-1439 (2007). (Pubitemid 350041474)
20. Gardiner, J.V., Jayasena, C.N. & Bloom, S.R. Gut hormones: a weight off your mind. J. Neuroendocrinol. 20, 834-841 (2008). (Pubitemid 351858737)
21. Baggio, L.L. & Drucker, D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 132, 2131-2157 (2007). (Pubitemid 46711096)
22. Jones, R.M., Leonard, J.N., Buzard, D.J. & Lehmann, J. GPR119 agonists for the treatment of type 2 diabetes. Expert Opin. Ther. Pat. 19, 1339-1359 (2009).
23. Sakamoto, Y. et al. Expression and distribution of Gpr119 in the pancreatic islets of mice and rats: predominant localization in pancreatic polypeptidesecreting PP-cells. Biochem. Biophys. Res. Commun. 351, 474-480 (2006). (Pubitemid 44666712)
24. T akeda, S., Kadowaki, S., Haga, T., Takaesu, H. & Mitaku, S. Identification of G protein-coupled receptor genes from the human genome sequence. FEBS Lett. 520, 97-101 (2002). (Pubitemid 34607281)
25. Soga, T. et al. Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem. Biophys. Res. Commun. 326, 744-751 (2005). (Pubitemid 39655983)
26. Overton, H.A. et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab. 3, 167-175 (2006).
27. Chu, Z.L. et al. N-oleoyldopamine enhances glucose homeostasis through the activation of GPR119. Mol. Endocrinol. 24, 161-170 (2010).
28. Semple, G. et al. Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119. J. Med. Chem. 51, 5172-5175 (2008).
29. Herman, G.A. et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin. Pharmacol. Ther. 78, 675-688 (2005). (Pubitemid 41773643)
30. Aaboe, K., Krarup, T., Madsbad, S. & Holst, J.J. GLP-1: physiological effects and potential therapeutic applications. Diabetes. Obes. Metab. 10, 994-1003 (2008).
31. Kjems, L.L., Holst, J.J., Vølund, A. & Madsbad, S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52, 380-386 (2003). (Pubitemid 36173193)
32. C hang, A.M. et al. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 52, 1786-1791 (2003). (Pubitemid 36792471)
33. Nauck, M.A. & Meier, J.J. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul. Pept. 128, 135-148 (2005). (Pubitemid 40380914)
34. Roberts, B. et al. MBX-2982, a novel oral GPR119 agonist for the treatment of type 2 diabetes: results of single and multiple dose studies. Diabetes. 58 (suppl. 1), A43, (2009).
35. Tanaka, H. et al. AS1907417, a novel GPR119 agonist, as an insulinotropic and beta-cell preservative agent for the treatment of type 2 diabetes. Diabetes. 58 (suppl. 1), A124 (2009)
36. Neary, M.T. & Batterham, R.L. Peptide YY: food for thought. Physiol. Behav. 97, 616-619 (2009).
37. Adrian, T.E. et al. Effect of peptide YY on gastric, pancreatic, and biliary function in humans. Gastroenterology 89, 494-499 (1985). (Pubitemid 15239150)
38. Batterham, R.L. et al. Inhibition of food intake in obese subjects by peptide YY3-36. N. Engl. J. Med. 349, 941-948 (2003). (Pubitemid 37064767)
39. Batterham, R.L. et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418, 650-654 (2002).
40. Chia, C.W. et al. Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. Diabetes 58, 1342-1349 (2009).
41. Gastaldelli, A. et al. Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes. Clin. Pharmacol. Ther. 81, 205-212 (2007). (Pubitemid 46174817)
42. Brandt, A., Katschinski, M., Arnold, R., Polonsky, K.S., Göke, B. & Byrne, M.M. GLP-1-induced alterations in the glucose-stimulated insulin secretory doseresponse curve. Am. J. Physiol. Endocrinol. Metab. 281, E242-E247 (2001).